Global Molecular Diagnostics Market Insights, Growth, Share, Size: By Offerings, By Technology, By Applications, By End Users, By Region & Segmental Forecast, 2023-2031, Comparative Analysis and Trends

  • Industry: Healthcare
  • Report ID: TNR-110-1050
  • Number of Pages: 420
  • Table/Charts : Yes
  • December, 2023
  • Base Year : 2024
  • No. of Companies : 14+
  • No. of Countries : 29
  • Views : 10061
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

Global Molecular Diagnostics Market was Valued at US$ 11.2 Bn in 2022, Growing at an Estimated CAGR of 9.86% During 2023 – 2031.

Molecular diagnostics refers to a collection of techniques and tests used in medical diagnostics to analyze biological markers at the molecular level. These biological markers can include DNA, RNA, proteins, and other molecules present in cells and tissues. The primary goal of molecular diagnostics is to detect specific genetic sequences, mutations, biomarkers, or pathogens associated with diseases.

Future of Global Molecular Diagnostics Market

While developments in molecular diagnostics are encouraging, there are a number of obstacles and future possibilities that must be addressed. To begin, the adoption and integration of molecular diagnostics into ordinary clinical practice need adequate infrastructure, healthcare professional training, and cost-effectiveness evaluations. Furthermore, as technology evolves, standardisation and quality control become increasingly important. It is critical for widespread deployment and acceptance of molecular diagnostic tests to ensure that they are accurate, consistent, and reliable across various laboratories.

Advances in molecular diagnostics have changed illness detection, giving healthcare providers more sensitive, specific, and speedy diagnostic tools. Molecular diagnostics has transformed the discipline, from improving sensitivity and specificity to the creation of quick POCT systems and the appearance of liquid biopsies. As technologies advance and constraints are overcome, the future of molecular diagnostics seems bright, with the potential to revolutionise illness diagnosis, improve patient outcomes, and, ultimately, save lives.

Global Molecular Diagnostics Market Revenue & Forecast, (US$ Million), 2015 – 2031

In recent years, several molecular diagnostics technologies have gained popularity and witnessed significant advancements, contributing to the evolution of the field. NGS technology has seen remarkable growth and adoption in the past few years. It enables rapid sequencing of DNA or RNA, allowing for the analysis of entire genomes, exomes, or targeted gene regions with high throughput. NGS is utilized in various applications, including oncology (tumor profiling, liquid biopsies), inherited diseases, infectious diseases, and pharmacogenomics.

Digital PCR has gained attention for its high precision and absolute quantification of nucleic acids. It offers improved sensitivity and accuracy by partitioning samples into thousands of individual reactions, making it useful in applications such as rare mutation detection, viral load quantification, and gene expression analysis.

SARS coronavirus, swine flu, MERS coronavirus, Ebola, and Zika virus outbreaks, as well as the continuing COVID-19 pandemic, have all underlined the critical need for strong surveillance and response procedures. Molecular diagnostics has evolved as a feasible and cost-effective option for infectious disease testing, particularly in resource-constrained settings with a wide range of possible infection sources. Due to their speed, complexity, and adaptability, they are extremely important, allowing healthcare systems to optimise resources and respond quickly to emergent dangers.

North America had the highest share in the molecular diagnostic market in 2022. North America holds a substantial share of the global molecular diagnostics market. The region’s market growth was driven by factors such as the increasing incidence of infectious diseases, rising demand for personalized medicine, advancements in healthcare infrastructure, and a proactive regulatory environment promoting the adoption of innovative diagnostic technologies. Recently at the American Association of Clinical Chemistry (AACC) Scientific Meeting and Clinical Lab Expo , Roche showcased its latest advancements, including the cobas 5800, a small, fully-automated molecular PCR-testing system with a broad range of assays, and cobas pure integrated solutions.

Competitive Landscape: Global Molecular Diagnostics Market

  • Abbott
  • BD
  • bioMérieux SA
  • Bio-Rad Laboratories
  • Danaher Corporation
  • DiaSorin S.p.A
  • F. Hoffmann-La Roche Ltd
  • Grifols
  • Hologic, Inc.
  • Promega Corporation
  • QIAGEN
  • Rapid Test Methods Ltd.
  • Seegene Inc.
  • Sysmex Europe SE.
  • Thermo Fisher Scientific Inc
  • Other Market Participants

Global Molecular Diagnostics Market

Report Specifications Details
Market Revenue in 2022 US$ 11.2 Bn
Market Size Forecast by 2031 US$ 25.1 Bn
Growth Rate (CAGR) 9.86%
Historic Data 2015 – 2021
Base Year for Estimation 2022
Forecast Period 2023 – 2031
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Offerings, By Technology, By Applications, By End Users
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players Abbott, BD, bioMérieux SA, Bio-Rad Laboratories, Danaher Corporation, DiaSorin S.p.A, F. Hoffmann-La Roche Ltd, Grifols, Hologic, Inc., Promega Corporation, QIAGEN, Rapid Test Methods Ltd., Seegene Inc., Sysmex Europe SE., Thermo Fisher Scientific Inc , Other Market Participants
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free): – +81 663-386-8111

South Korea (Toll-Free): – +82-808- 703-126

Saudi Arabia (Toll-Free): – +966 800 850 1643

United States: +1 302-232-5106

United Kingdom: +447537105080

E-mail:  askanexpert@thenicheresearch.com

 

 

Global Molecular Diagnostics Market Scope By Offerings

  • Instruments
  • Solutions
  • Reagents and Kits

By Technology

  • Polymerase chain reaction (PCR)
  • Nucleic Acid Amplification Tests (NAATs)
  • Next-generation sequencing (NGS)
  • Fluorescence In situ hybridization
  • Microarray Technology
  • CRISP-R
  • Others

By Application

  • Infectious diseases
    • Meningitis
    • Chlamydia
    • Gonorrhea
    • HIV
    • Carbapenem-resistant Bacteria
    • Flu
    • Respiratory Syncytial Virus (RSV)
    • Candida
    • Others
  • Oncology
    • Breast Cancer
    • Prostate Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Kidney Cancer
    • Liver Cancer
    • Blood Cancer
    • Lung Cancer
    • Others
  • Pharamacogenomics
  • Hematopathology
  • Genetic Testing
  • Neurological Diseases
  • Cardiovascular Diseases
  • Others

By End Users

  • Clinical Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Research Institutions

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

Report Coverage and Deliverables:

Table of Contents

.

1.Market Scope
1.1.Market Segmentation
1.2.Years Considered
1.2.1.Historic Years: 2015 - 2021
1.2.2.Base Year: 2022
1.2.3.Forecast Years: 2023 – 2031
2.Key Target Audiences
3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire
3.1.2.Global Percentage Breakdown
3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)
3.2.Secondary Research
3.2.1.Paid Databases
3.2.2.Secondary Sources
3.3.Market Size Estimates
3.3.1.Top-Down Approach
3.3.2.Bottom-Up Approach
3.4.Data Triangulation Methodology
3.5.Research Assumptions
4.Recommendations and Insights from TNR’s Perspective**
5.Holistic Overview of Molecular Diagnostics Market
6.Market Synopsis: Molecular Diagnostics Market
7.Molecular Diagnostics Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition
7.1.2.Industry Development
7.2.Market Dynamics
7.2.1.Drivers
7.2.2.Restraints
7.2.3.Opportunities
7.3.Trends in Molecular Diagnostics Market
7.4.Market Determinants Radar Chart
7.5.Macro-Economic and Micro-Economic Indicators: Molecular Diagnostics Market
7.6.Porter’s Five Force Analysis
7.7.Impact of Covid-19 on Molecular Diagnostics Market
8.Global Molecular Diagnostics Market Analysis and Forecasts, 2023 – 2031
8.1.Overview
8.1.1.Global Molecular Diagnostics Market Revenue (US$ Mn)
8.2.Global Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
8.2.1.Instruments
8.2.1.1.Definition
8.2.1.2.Market Estimation and Penetration, 2015 - 2022
8.2.1.3.Market Forecast, 2023 – 2031
8.2.1.4.Compound Annual Growth Rate (CAGR)
8.2.1.5.Regional Bifurcation
8.2.1.5.1.North America
8.2.1.5.1.1.Market Estimation, 2015 - 2022
8.2.1.5.1.2.Market Forecast, 2023 – 2031
8.2.1.5.2.Europe
8.2.1.5.2.1.Market Estimation, 2015 - 2022
8.2.1.5.2.2.Market Forecast, 2023 – 2031
8.2.1.5.3.Asia Pacific
8.2.1.5.3.1.Market Estimation, 2015 - 2022
8.2.1.5.3.2.Market Forecast, 2023 – 2031
8.2.1.5.4.Middle East and Africa
8.2.1.5.4.1.Market Estimation, 2015 - 2022
8.2.1.5.4.2.Market Forecast, 2023 – 2031
8.2.1.5.5.Latin America
8.2.1.5.5.1.Market Estimation, 2015 - 2022
8.2.1.5.5.2.Market Forecast, 2023 – 2031
8.2.2.Solutions
8.2.2.1.Definition
8.2.2.2.Market Estimation and Penetration, 2015 - 2022
8.2.2.3.Market Forecast, 2023 – 2031
8.2.2.4.Compound Annual Growth Rate (CAGR)
8.2.2.5.Regional Bifurcation
8.2.2.5.1.North America
8.2.2.5.1.1.Market Estimation, 2015 - 2022
8.2.2.5.1.2.Market Forecast, 2023 – 2031
8.2.2.5.2.Europe
8.2.2.5.2.1.Market Estimation, 2015 - 2022
8.2.2.5.2.2.Market Forecast, 2023 – 2031
8.2.2.5.3.Asia Pacific
8.2.2.5.3.1.Market Estimation, 2015 - 2022
8.2.2.5.3.2.Market Forecast, 2023 – 2031
8.2.2.5.4.Middle East and Africa
8.2.2.5.4.1.Market Estimation, 2015 - 2022
8.2.2.5.4.2.Market Forecast, 2023 – 2031
8.2.2.5.5.Latin America
8.2.2.5.5.1.Market Estimation, 2015 - 2022
8.2.2.5.5.2.Market Forecast, 2023 – 2031
8.2.3.Reagents and Kits
8.2.3.1.Definition
8.2.3.2.Market Estimation and Penetration, 2015 - 2022
8.2.3.3.Market Forecast, 2023 – 2031
8.2.3.4.Compound Annual Growth Rate (CAGR)
8.2.3.5.Regional Bifurcation
8.2.3.5.1.North America
8.2.3.5.1.1.Market Estimation, 2015 - 2022
8.2.3.5.1.2.Market Forecast, 2023 – 2031
8.2.3.5.2.Europe
8.2.3.5.2.1.Market Estimation, 2015 - 2022
8.2.3.5.2.2.Market Forecast, 2023 – 2031
8.2.3.5.3.Asia Pacific
8.2.3.5.3.1.Market Estimation, 2015 - 2022
8.2.3.5.3.2.Market Forecast, 2023 – 2031
8.2.3.5.4.Middle East and Africa
8.2.3.5.4.1.Market Estimation, 2015 - 2022
8.2.3.5.4.2.Market Forecast, 2023 – 2031
8.2.3.5.5.Latin America
8.2.3.5.5.1.Market Estimation, 2015 - 2022
8.2.3.5.5.2.Market Forecast, 2023 – 2031
8.3.Key Segment for Channeling Investments
8.3.1.By Offerings
9.Global Molecular Diagnostics Market Analysis and Forecasts, 2023 – 2031
9.1.Overview
9.2.Global Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
9.2.1.Polymerase chain reaction (PCR)
9.2.1.1.Definition
9.2.1.2.Market Estimation and Penetration, 2015 - 2022
9.2.1.3.Market Forecast, 2023 – 2031
9.2.1.4.Compound Annual Growth Rate (CAGR)
9.2.1.5.Regional Bifurcation
9.2.1.5.1.North America
9.2.1.5.1.1.Market Estimation, 2015 - 2022
9.2.1.5.1.2.Market Forecast, 2023 – 2031
9.2.1.5.2.Europe
9.2.1.5.2.1.Market Estimation, 2015 - 2022
9.2.1.5.2.2.Market Forecast, 2023 – 2031
9.2.1.5.3.Asia Pacific
9.2.1.5.3.1.Market Estimation, 2015 - 2022
9.2.1.5.3.2.Market Forecast, 2023 – 2031
9.2.1.5.4.Middle East and Africa
9.2.1.5.4.1.Market Estimation, 2015 - 2022
9.2.1.5.4.2.Market Forecast, 2023 – 2031
9.2.1.5.5.Latin America
9.2.1.5.5.1.Market Estimation, 2015 - 2022
9.2.1.5.5.2.Market Forecast, 2023 – 2031
9.2.2.Nucleic Acid Amplification Tests (NAATs)
9.2.2.1.Definition
9.2.2.2.Market Estimation and Penetration, 2015 - 2022
9.2.2.3.Market Forecast, 2023 – 2031
9.2.2.4.Compound Annual Growth Rate (CAGR)
9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2015 - 2022
9.2.2.5.1.2.Market Forecast, 2023 – 2031
9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2015 - 2022
9.2.2.5.2.2.Market Forecast, 2023 – 2031
9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2015 - 2022
9.2.2.5.3.2.Market Forecast, 2023 – 2031
9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2015 - 2022
9.2.2.5.4.2.Market Forecast, 2023 – 2031
9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2015 - 2022
9.2.2.5.5.2.Market Forecast, 2023 – 2031
9.2.3.Next-generation sequencing (NGS)
9.2.3.1.Definition
9.2.3.2.Market Estimation and Penetration, 2015 - 2022
9.2.3.3.Market Forecast, 2023 – 2031
9.2.3.4.Compound Annual Growth Rate (CAGR)
9.2.3.5.Regional Bifurcation
9.2.3.5.1.North America
9.2.3.5.1.1.Market Estimation, 2015 - 2022
9.2.3.5.1.2.Market Forecast, 2023 – 2031
9.2.3.5.2.Europe
9.2.3.5.2.1.Market Estimation, 2015 - 2022
9.2.3.5.2.2.Market Forecast, 2023 – 2031
9.2.3.5.3.Asia Pacific
9.2.3.5.3.1.Market Estimation, 2015 - 2022
9.2.3.5.3.2.Market Forecast, 2023 – 2031
9.2.3.5.4.Middle East and Africa
9.2.3.5.4.1.Market Estimation, 2015 - 2022
9.2.3.5.4.2.Market Forecast, 2023 – 2031
9.2.3.5.5.Latin America
9.2.3.5.5.1.Market Estimation, 2015 - 2022
9.2.3.5.5.2.Market Forecast, 2023 – 2031
9.2.4.Fluorescence In situ hybridization
9.2.4.1.Definition
9.2.4.2.Market Estimation and Penetration, 2015 - 2022
9.2.4.3.Market Forecast, 2023 – 2031
9.2.4.4.Compound Annual Growth Rate (CAGR)
9.2.4.5.Regional Bifurcation
9.2.4.5.1.North America
9.2.4.5.1.1.Market Estimation, 2015 - 2022
9.2.4.5.1.2.Market Forecast, 2023 – 2031
9.2.4.5.2.Europe
9.2.4.5.2.1.Market Estimation, 2015 - 2022
9.2.4.5.2.2.Market Forecast, 2023 – 2031
9.2.4.5.3.Asia Pacific
9.2.4.5.3.1.Market Estimation, 2015 - 2022
9.2.4.5.3.2.Market Forecast, 2023 – 2031
9.2.4.5.4.Middle East and Africa
9.2.4.5.4.1.Market Estimation, 2015 - 2022
9.2.4.5.4.2.Market Forecast, 2023 – 2031
9.2.4.5.5.Latin America
9.2.4.5.5.1.Market Estimation, 2015 - 2022
9.2.4.5.5.2.Market Forecast, 2023 – 2031
9.2.5.Microarray Technology
9.2.5.1.Definition
9.2.5.2.Market Estimation and Penetration, 2015 - 2022
9.2.5.3.Market Forecast, 2023 – 2031
9.2.5.4.Compound Annual Growth Rate (CAGR)
9.2.5.5.Regional Bifurcation
9.2.5.5.1.North America
9.2.5.5.1.1.Market Estimation, 2015 - 2022
9.2.5.5.1.2.Market Forecast, 2023 – 2031
9.2.5.5.2.Europe
9.2.5.5.2.1.Market Estimation, 2015 - 2022
9.2.5.5.2.2.Market Forecast, 2023 – 2031
9.2.5.5.3.Asia Pacific
9.2.5.5.3.1.Market Estimation, 2015 - 2022
9.2.5.5.3.2.Market Forecast, 2023 – 2031
9.2.5.5.4.Middle East and Africa
9.2.5.5.4.1.Market Estimation, 2015 - 2022
9.2.5.5.4.2.Market Forecast, 2023 – 2031
9.2.5.5.5.Latin America
9.2.5.5.5.1.Market Estimation, 2015 - 2022
9.2.5.5.5.2.Market Forecast, 2023 – 2031
9.2.6.CRISP-R
9.2.6.1.Definition
9.2.6.2.Market Estimation and Penetration, 2015 - 2022
9.2.6.3.Market Forecast, 2023 – 2031
9.2.6.4.Compound Annual Growth Rate (CAGR)
9.2.6.5.Regional Bifurcation
9.2.6.5.1.North America
9.2.6.5.1.1.Market Estimation, 2015 - 2022
9.2.6.5.1.2.Market Forecast, 2023 – 2031
9.2.6.5.2.Europe
9.2.6.5.2.1.Market Estimation, 2015 - 2022
9.2.6.5.2.2.Market Forecast, 2023 – 2031
9.2.6.5.3.Asia Pacific
9.2.6.5.3.1.Market Estimation, 2015 - 2022
9.2.6.5.3.2.Market Forecast, 2023 – 2031
9.2.6.5.4.Middle East and Africa
9.2.6.5.4.1.Market Estimation, 2015 - 2022
9.2.6.5.4.2.Market Forecast, 2023 – 2031
9.2.6.5.5.Latin America
9.2.6.5.5.1.Market Estimation, 2015 - 2022
9.2.6.5.5.2.Market Forecast, 2023 – 2031
9.2.7.Others
9.2.7.1.Definition
9.2.7.2.Market Estimation and Penetration, 2015 - 2022
9.2.7.3.Market Forecast, 2023 – 2031
9.2.7.4.Compound Annual Growth Rate (CAGR)
9.2.7.5.Regional Bifurcation
9.2.7.5.1.North America
9.2.7.5.1.1.Market Estimation, 2015 - 2022
9.2.7.5.1.2.Market Forecast, 2023 – 2031
9.2.7.5.2.Europe
9.2.7.5.2.1.Market Estimation, 2015 - 2022
9.2.7.5.2.2.Market Forecast, 2023 – 2031
9.2.7.5.3.Asia Pacific
9.2.7.5.3.1.Market Estimation, 2015 - 2022
9.2.7.5.3.2.Market Forecast, 2023 – 2031
9.2.7.5.4.Middle East and Africa
9.2.7.5.4.1.Market Estimation, 2015 - 2022
9.2.7.5.4.2.Market Forecast, 2023 – 2031
9.2.7.5.5.Latin America
9.2.7.5.5.1.Market Estimation, 2015 - 2022
9.2.7.5.5.2.Market Forecast, 2023 – 2031
9.3.Key Segment for Channeling Investments
9.3.1.By Technology
10.Global Molecular Diagnostics Market Analysis and Forecasts, 2023 – 2031
10.1.Overview
10.2.Global Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
10.2.1.Infectious diseases (Definition, Market Estimation and Penetration, 2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 – 2031 ), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Meningitis, Chlamydia, Gonorrhea, HIV, Carbapenem-resistant Bacteria, Flu, Respiratory Syncytial Virus (RSV), Candida, Others )
10.2.1.1.Meningitis
10.2.1.2.Chlamydia
10.2.1.3.Gonorrhea
10.2.1.4.HIV
10.2.1.5.Carbapenem-resistant Bacteria
10.2.1.6.Flu
10.2.1.7.Respiratory Syncytial Virus (RSV)
10.2.1.8.Candida
10.2.1.9.Others
10.2.2.Oncology (Definition, Market Estimation and Penetration, 2015 - 2022, Market Estimation (2015 - 2022), Market Forecast (2023 – 2031 ), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Breast Cancer , Prostate Cancer, Colorectal Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Blood Cancer, Lung Cancer, Others )
10.2.2.1.Breast Cancer
10.2.2.2.Prostate Cancer
10.2.2.3.Colorectal Cancer
10.2.2.4.Cervical Cancer
10.2.2.5.Kidney Cancer
10.2.2.6.Liver Cancer
10.2.2.7.Blood Cancer
10.2.2.8.Lung Cancer
10.2.2.9.Others
10.2.3.Pharamacogenomics
10.2.3.1.Definition
10.2.3.2.Market Estimation and Penetration, 2015 - 2022
10.2.3.3.Market Forecast, 2023 – 2031
10.2.3.4.Compound Annual Growth Rate (CAGR)
10.2.3.5.Regional Bifurcation
10.2.3.5.1.North America
10.2.3.5.1.1.Market Estimation, 2015 - 2022
10.2.3.5.1.2.Market Forecast, 2023 – 2031
10.2.3.5.2.Europe
10.2.3.5.2.1.Market Estimation, 2015 - 2022
10.2.3.5.2.2.Market Forecast, 2023 – 2031
10.2.3.5.3.Asia Pacific
10.2.3.5.3.1.Market Estimation, 2015 - 2022
10.2.3.5.3.2.Market Forecast, 2023 – 2031
10.2.3.5.4.Middle East and Africa
10.2.3.5.4.1.Market Estimation, 2015 - 2022
10.2.3.5.4.2.Market Forecast, 2023 – 2031
10.2.3.5.5.Latin America
10.2.3.5.5.1.Market Estimation, 2015 - 2022
10.2.3.5.5.2.Market Forecast, 2023 – 2031
10.2.4.Hematopathology
10.2.4.1.Definition
10.2.4.2.Market Estimation and Penetration, 2015 - 2022
10.2.4.3.Market Forecast, 2023 – 2031
10.2.4.4.Compound Annual Growth Rate (CAGR)
10.2.4.5.Regional Bifurcation
10.2.4.5.1.North America
10.2.4.5.1.1.Market Estimation, 2015 - 2022
10.2.4.5.1.2.Market Forecast, 2023 – 2031
10.2.4.5.2.Europe
10.2.4.5.2.1.Market Estimation, 2015 - 2022
10.2.4.5.2.2.Market Forecast, 2023 – 2031
10.2.4.5.3.Asia Pacific
10.2.4.5.3.1.Market Estimation, 2015 - 2022
10.2.4.5.3.2.Market Forecast, 2023 – 2031
10.2.4.5.4.Middle East and Africa
10.2.4.5.4.1.Market Estimation, 2015 - 2022
10.2.4.5.4.2.Market Forecast, 2023 – 2031
10.2.4.5.5.Latin America
10.2.4.5.5.1.Market Estimation, 2015 - 2022
10.2.4.5.5.2.Market Forecast, 2023 – 2031
10.2.5.Genetic Testing
10.2.5.1.Definition
10.2.5.2.Market Estimation and Penetration, 2015 - 2022
10.2.5.3.Market Forecast, 2023 – 2031
10.2.5.4.Compound Annual Growth Rate (CAGR)
10.2.5.5.Regional Bifurcation
10.2.5.5.1.North America
10.2.5.5.1.1.Market Estimation, 2015 - 2022
10.2.5.5.1.2.Market Forecast, 2023 – 2031
10.2.5.5.2.Europe
10.2.5.5.2.1.Market Estimation, 2015 - 2022
10.2.5.5.2.2.Market Forecast, 2023 – 2031
10.2.5.5.3.Asia Pacific
10.2.5.5.3.1.Market Estimation, 2015 - 2022
10.2.5.5.3.2.Market Forecast, 2023 – 2031
10.2.5.5.4.Middle East and Africa
10.2.5.5.4.1.Market Estimation, 2015 - 2022
10.2.5.5.4.2.Market Forecast, 2023 – 2031
10.2.5.5.5.Latin America
10.2.5.5.5.1.Market Estimation, 2015 - 2022
10.2.5.5.5.2.Market Forecast, 2023 – 2031
10.2.6.Neurological Diseases
10.2.6.1.Definition
10.2.6.2.Market Estimation and Penetration, 2015 - 2022
10.2.6.3.Market Forecast, 2023 – 2031
10.2.6.4.Compound Annual Growth Rate (CAGR)
10.2.6.5.Regional Bifurcation
10.2.6.5.1.North America
10.2.6.5.1.1.Market Estimation, 2015 - 2022
10.2.6.5.1.2.Market Forecast, 2023 – 2031
10.2.6.5.2.Europe
10.2.6.5.2.1.Market Estimation, 2015 - 2022
10.2.6.5.2.2.Market Forecast, 2023 – 2031
10.2.6.5.3.Asia Pacific
10.2.6.5.3.1.Market Estimation, 2015 - 2022
10.2.6.5.3.2.Market Forecast, 2023 – 2031
10.2.6.5.4.Middle East and Africa
10.2.6.5.4.1.Market Estimation, 2015 - 2022
10.2.6.5.4.2.Market Forecast, 2023 – 2031
10.2.6.5.5.Latin America
10.2.6.5.5.1.Market Estimation, 2015 - 2022
10.2.6.5.5.2.Market Forecast, 2023 – 2031
10.2.7.Cardiovascular Diseases
10.2.7.1.Definition
10.2.7.2.Market Estimation and Penetration, 2015 - 2022
10.2.7.3.Market Forecast, 2023 – 2031
10.2.7.4.Compound Annual Growth Rate (CAGR)
10.2.7.5.Regional Bifurcation
10.2.7.5.1.North America
10.2.7.5.1.1.Market Estimation, 2015 - 2022
10.2.7.5.1.2.Market Forecast, 2023 – 2031
10.2.7.5.2.Europe
10.2.7.5.2.1.Market Estimation, 2015 - 2022
10.2.7.5.2.2.Market Forecast, 2023 – 2031
10.2.7.5.3.Asia Pacific
10.2.7.5.3.1.Market Estimation, 2015 - 2022
10.2.7.5.3.2.Market Forecast, 2023 – 2031
10.2.7.5.4.Middle East and Africa
10.2.7.5.4.1.Market Estimation, 2015 - 2022
10.2.7.5.4.2.Market Forecast, 2023 – 2031
10.2.7.5.5.Latin America
10.2.7.5.5.1.Market Estimation, 2015 - 2022
10.2.7.5.5.2.Market Forecast, 2023 – 2031
10.2.8.Others
10.2.8.1.Definition
10.2.8.2.Market Estimation and Penetration, 2015 - 2022
10.2.8.3.Market Forecast, 2023 – 2031
10.2.8.4.Compound Annual Growth Rate (CAGR)
10.2.8.5.Regional Bifurcation
10.2.8.5.1.North America
10.2.8.5.1.1.Market Estimation, 2015 - 2022
10.2.8.5.1.2.Market Forecast, 2023 – 2031
10.2.8.5.2.Europe
10.2.8.5.2.1.Market Estimation, 2015 - 2022
10.2.8.5.2.2.Market Forecast, 2023 – 2031
10.2.8.5.3.Asia Pacific
10.2.8.5.3.1.Market Estimation, 2015 - 2022
10.2.8.5.3.2.Market Forecast, 2023 – 2031
10.2.8.5.4.Middle East and Africa
10.2.8.5.4.1.Market Estimation, 2015 - 2022
10.2.8.5.4.2.Market Forecast, 2023 – 2031
10.2.8.5.5.Latin America
10.2.8.5.5.1.Market Estimation, 2015 - 2022
10.2.8.5.5.2.Market Forecast, 2023 – 2031
10.3.Key Segment for Channeling Investments
10.3.1.By Application
11.Global Molecular Diagnostics Market Analysis and Forecasts, 2023 – 2031
11.1.Overview
11.2.Global Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
11.2.1.Clinical Laboratories
11.2.1.1.Definition
11.2.1.2.Market Estimation and Penetration, 2015 - 2022
11.2.1.3.Market Forecast, 2023 – 2031
11.2.1.4.Compound Annual Growth Rate (CAGR)
11.2.1.5.Regional Bifurcation
11.2.1.5.1.North America
11.2.1.5.1.1.Market Estimation, 2015 - 2022
11.2.1.5.1.2.Market Forecast, 2023 – 2031
11.2.1.5.2.Europe
11.2.1.5.2.1.Market Estimation, 2015 - 2022
11.2.1.5.2.2.Market Forecast, 2023 – 2031
11.2.1.5.3.Asia Pacific
11.2.1.5.3.1.Market Estimation, 2015 - 2022
11.2.1.5.3.2.Market Forecast, 2023 – 2031
11.2.1.5.4.Middle East and Africa
11.2.1.5.4.1.Market Estimation, 2015 - 2022
11.2.1.5.4.2.Market Forecast, 2023 – 2031
11.2.1.5.5.Latin America
11.2.1.5.5.1.Market Estimation, 2015 - 2022
11.2.1.5.5.2.Market Forecast, 2023 – 2031
11.2.2.Pharmaceutical and Biotechnology Companies
11.2.2.1.Definition
11.2.2.2.Market Estimation and Penetration, 2015 - 2022
11.2.2.3.Market Forecast, 2023 – 2031
11.2.2.4.Compound Annual Growth Rate (CAGR)
11.2.2.5.Regional Bifurcation
11.2.2.5.1.North America
11.2.2.5.1.1.Market Estimation, 2015 - 2022
11.2.2.5.1.2.Market Forecast, 2023 – 2031
11.2.2.5.2.Europe
11.2.2.5.2.1.Market Estimation, 2015 - 2022
11.2.2.5.2.2.Market Forecast, 2023 – 2031
11.2.2.5.3.Asia Pacific
11.2.2.5.3.1.Market Estimation, 2015 - 2022
11.2.2.5.3.2.Market Forecast, 2023 – 2031
11.2.2.5.4.Middle East and Africa
11.2.2.5.4.1.Market Estimation, 2015 - 2022
11.2.2.5.4.2.Market Forecast, 2023 – 2031
11.2.2.5.5.Latin America
11.2.2.5.5.1.Market Estimation, 2015 - 2022
11.2.2.5.5.2.Market Forecast, 2023 – 2031
11.2.3.Research Institutions
11.2.3.1.Definition
11.2.3.2.Market Estimation and Penetration, 2015 - 2022
11.2.3.3.Market Forecast, 2023 – 2031
11.2.3.4.Compound Annual Growth Rate (CAGR)
11.2.3.5.Regional Bifurcation
11.2.3.5.1.North America
11.2.3.5.1.1.Market Estimation, 2015 - 2022
11.2.3.5.1.2.Market Forecast, 2023 – 2031
11.2.3.5.2.Europe
11.2.3.5.2.1.Market Estimation, 2015 - 2022
11.2.3.5.2.2.Market Forecast, 2023 – 2031
11.2.3.5.3.Asia Pacific
11.2.3.5.3.1.Market Estimation, 2015 - 2022
11.2.3.5.3.2.Market Forecast, 2023 – 2031
11.2.3.5.4.Middle East and Africa
11.2.3.5.4.1.Market Estimation, 2015 - 2022
11.2.3.5.4.2.Market Forecast, 2023 – 2031
11.2.3.5.5.Latin America
11.2.3.5.5.1.Market Estimation, 2015 - 2022
11.2.3.5.5.2.Market Forecast, 2023 – 2031
11.3.Key Segment for Channeling Investments
11.3.1.By End Users
12.North America Molecular Diagnostics Market Analysis and Forecasts, 2023 – 2031
12.1.Overview
12.1.1.North America Molecular Diagnostics Market Revenue (US$ Mn)
12.2.North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
12.2.1.Instruments
12.2.2.Solutions
12.2.3.Reagents and Kits
12.3.North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
12.3.1.Polymerase chain reaction (PCR)
12.3.2.Nucleic Acid Amplification Tests (NAATs)
12.3.3.Next-generation sequencing (NGS)
12.3.4.Fluorescence In situ hybridization
12.3.5.Microarray Technology
12.3.6.CRISP-R
12.3.7.Others
12.4.North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.4.1.Infectious diseases
12.4.1.1.Meningitis
12.4.1.2.Chlamydia
12.4.1.3.Gonorrhea
12.4.1.4.HIV
12.4.1.5.Carbapenem-resistant Bacteria
12.4.1.6.Flu
12.4.1.7.Respiratory Syncytial Virus (RSV)
12.4.1.8.Candida
12.4.1.9.Others
12.4.2.Oncology
12.4.2.1.Breast Cancer
12.4.2.2.Prostate Cancer
12.4.2.3.Colorectal Cancer
12.4.2.4.Cervical Cancer
12.4.2.5.Kidney Cancer
12.4.2.6.Liver Cancer
12.4.2.7.Blood Cancer
12.4.2.8.Lung Cancer
12.4.2.9.Others
12.4.3.Pharamacogenomics
12.4.4.Hematopathology
12.4.5.Genetic Testing
12.4.6.Neurological Diseases
12.4.7.Cardiovascular Diseases
12.4.8.Others
12.5.North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.1.Clinical Laboratories
12.5.2.Pharmaceutical and Biotechnology Companies
12.5.3.Research Institutions
12.6.North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1.U.S
12.6.1.1.U.S Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
12.6.1.1.1.Instruments
12.6.1.1.2.Solutions
12.6.1.1.3.Reagents and Kits
12.6.1.2.U.S Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
12.6.1.2.1.Polymerase chain reaction (PCR)
12.6.1.2.2.Nucleic Acid Amplification Tests (NAATs)
12.6.1.2.3.Next-generation sequencing (NGS)
12.6.1.2.4.Fluorescence In situ hybridization
12.6.1.2.5.Microarray Technology
12.6.1.2.6.CRISP-R
12.6.1.2.7.Others
12.6.1.3.U.S Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.6.1.3.1.Infectious diseases
12.6.1.3.1.1.Meningitis
12.6.1.3.1.2.Chlamydia
12.6.1.3.1.3.Gonorrhea
12.6.1.3.1.4.HIV
12.6.1.3.1.5.Carbapenem-resistant Bacteria
12.6.1.3.1.6.Flu
12.6.1.3.1.7.Respiratory Syncytial Virus (RSV)
12.6.1.3.1.8.Candida
12.6.1.3.1.9.Others
12.6.1.3.2.Oncology
12.6.1.3.2.1.Breast Cancer
12.6.1.3.2.2.Prostate Cancer
12.6.1.3.2.3.Colorectal Cancer
12.6.1.3.2.4.Cervical Cancer
12.6.1.3.2.5.Kidney Cancer
12.6.1.3.2.6.Liver Cancer
12.6.1.3.2.7.Blood Cancer
12.6.1.3.2.8.Lung Cancer
12.6.1.3.2.9.Others
12.6.1.3.3.Pharamacogenomics
12.6.1.3.4.Hematopathology
12.6.1.3.5.Genetic Testing
12.6.1.3.6.Neurological Diseases
12.6.1.3.7.Cardiovascular Diseases
12.6.1.3.8.Others
12.6.1.4.U.S Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.1.4.1.Clinical Laboratories
12.6.1.4.2.Pharmaceutical and Biotechnology Companies
12.6.1.4.3.Research Institutions
12.6.2.Canada
12.6.2.1.Canada Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
12.6.2.1.1.Instruments
12.6.2.1.2.Solutions
12.6.2.1.3.Reagents and Kits
12.6.2.2.Canada Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
12.6.2.2.1.Polymerase chain reaction (PCR)
12.6.2.2.2.Nucleic Acid Amplification Tests (NAATs)
12.6.2.2.3.Next-generation sequencing (NGS)
12.6.2.2.4.Fluorescence In situ hybridization
12.6.2.2.5.Microarray Technology
12.6.2.2.6.CRISP-R
12.6.2.2.7.Others
12.6.2.3.Canada Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.6.2.3.1.Infectious diseases
12.6.2.3.1.1.Meningitis
12.6.2.3.1.2.Chlamydia
12.6.2.3.1.3.Gonorrhea
12.6.2.3.1.4.HIV
12.6.2.3.1.5.Carbapenem-resistant Bacteria
12.6.2.3.1.6.Flu
12.6.2.3.1.7.Respiratory Syncytial Virus (RSV)
12.6.2.3.1.8.Candida
12.6.2.3.1.9.Others
12.6.2.3.2.Oncology
12.6.2.3.2.1.Breast Cancer
12.6.2.3.2.2.Prostate Cancer
12.6.2.3.2.3.Colorectal Cancer
12.6.2.3.2.4.Cervical Cancer
12.6.2.3.2.5.Kidney Cancer
12.6.2.3.2.6.Liver Cancer
12.6.2.3.2.7.Blood Cancer
12.6.2.3.2.8.Lung Cancer
12.6.2.3.2.9.Others
12.6.2.3.3.Pharamacogenomics
12.6.2.3.4.Hematopathology
12.6.2.3.5.Genetic Testing
12.6.2.3.6.Neurological Diseases
12.6.2.3.7.Cardiovascular Diseases
12.6.2.3.8.Others
12.6.2.4.Canada Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.2.4.1.Clinical Laboratories
12.6.2.4.2.Pharmaceutical and Biotechnology Companies
12.6.2.4.3.Research Institutions
12.6.3.Mexico
12.6.3.1.Mexico Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
12.6.3.1.1.Instruments
12.6.3.1.2.Solutions
12.6.3.1.3.Reagents and Kits
12.6.3.2.Mexico Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
12.6.3.2.1.Polymerase chain reaction (PCR)
12.6.3.2.2.Nucleic Acid Amplification Tests (NAATs)
12.6.3.2.3.Next-generation sequencing (NGS)
12.6.3.2.4.Fluorescence In situ hybridization
12.6.3.2.5.Microarray Technology
12.6.3.2.6.CRISP-R
12.6.3.2.7.Others
12.6.3.3.Mexico Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.6.3.3.1.Infectious diseases
12.6.3.3.1.1.Meningitis
12.6.3.3.1.2.Chlamydia
12.6.3.3.1.3.Gonorrhea
12.6.3.3.1.4.HIV
12.6.3.3.1.5.Carbapenem-resistant Bacteria
12.6.3.3.1.6.Flu
12.6.3.3.1.7.Respiratory Syncytial Virus (RSV)
12.6.3.3.1.8.Candida
12.6.3.3.1.9.Others
12.6.3.3.2.Oncology
12.6.3.3.2.1.Breast Cancer
12.6.3.3.2.2.Prostate Cancer
12.6.3.3.2.3.Colorectal Cancer
12.6.3.3.2.4.Cervical Cancer
12.6.3.3.2.5.Kidney Cancer
12.6.3.3.2.6.Liver Cancer
12.6.3.3.2.7.Blood Cancer
12.6.3.3.2.8.Lung Cancer
12.6.3.3.2.9.Others
12.6.3.3.3.Pharamacogenomics
12.6.3.3.4.Hematopathology
12.6.3.3.5.Genetic Testing
12.6.3.3.6.Neurological Diseases
12.6.3.3.7.Cardiovascular Diseases
12.6.3.3.8.Others
12.6.3.4.Mexico Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.3.4.1.Clinical Laboratories
12.6.3.4.2.Pharmaceutical and Biotechnology Companies
12.6.3.4.3.Research Institutions
12.6.4.Rest of North America
12.6.4.1.Rest of North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
12.6.4.1.1.Instruments
12.6.4.1.2.Solutions
12.6.4.1.3.Reagents and Kits
12.6.4.2.Rest of North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
12.6.4.2.1.Polymerase chain reaction (PCR)
12.6.4.2.2.Nucleic Acid Amplification Tests (NAATs)
12.6.4.2.3.Next-generation sequencing (NGS)
12.6.4.2.4.Fluorescence In situ hybridization
12.6.4.2.5.Microarray Technology
12.6.4.2.6.CRISP-R
12.6.4.2.7.Others
12.6.4.3.Rest of North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
12.6.4.3.1.Infectious diseases
12.6.4.3.1.1.Meningitis
12.6.4.3.1.2.Chlamydia
12.6.4.3.1.3.Gonorrhea
12.6.4.3.1.4.HIV
12.6.4.3.1.5.Carbapenem-resistant Bacteria
12.6.4.3.1.6.Flu
12.6.4.3.1.7.Respiratory Syncytial Virus (RSV)
12.6.4.3.1.8.Candida
12.6.4.3.1.9.Others
12.6.4.3.2.Oncology
12.6.4.3.2.1.Breast Cancer
12.6.4.3.2.2.Prostate Cancer
12.6.4.3.2.3.Colorectal Cancer
12.6.4.3.2.4.Cervical Cancer
12.6.4.3.2.5.Kidney Cancer
12.6.4.3.2.6.Liver Cancer
12.6.4.3.2.7.Blood Cancer
12.6.4.3.2.8.Lung Cancer
12.6.4.3.2.9.Others
12.6.4.3.3.Pharamacogenomics
12.6.4.3.4.Hematopathology
12.6.4.3.5.Genetic Testing
12.6.4.3.6.Neurological Diseases
12.6.4.3.7.Cardiovascular Diseases
12.6.4.3.8.Others
12.6.4.4.Rest of North America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
12.6.4.4.1.Clinical Laboratories
12.6.4.4.2.Pharmaceutical and Biotechnology Companies
12.6.4.4.3.Research Institutions
12.7.Key Segment for Channeling Investments
12.7.1.By Country
12.7.2.By Offerings
12.7.3.By Technology
12.7.4.By Application
12.7.5.By End Users
13.Europe Molecular Diagnostics Market Analysis and Forecasts, 2023 – 2031
13.1.Overview
13.1.1.Europe Molecular Diagnostics Market Revenue (US$ Mn)
13.2.Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
13.2.1.Instruments
13.2.2.Solutions
13.2.3.Reagents and Kits
13.3.Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.3.1.Polymerase chain reaction (PCR)
13.3.2.Nucleic Acid Amplification Tests (NAATs)
13.3.3.Next-generation sequencing (NGS)
13.3.4.Fluorescence In situ hybridization
13.3.5.Microarray Technology
13.3.6.CRISP-R
13.3.7.Others
13.4.Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.4.1.Infectious diseases
13.4.1.1.Meningitis
13.4.1.2.Chlamydia
13.4.1.3.Gonorrhea
13.4.1.4.HIV
13.4.1.5.Carbapenem-resistant Bacteria
13.4.1.6.Flu
13.4.1.7.Respiratory Syncytial Virus (RSV)
13.4.1.8.Candida
13.4.1.9.Others
13.4.2.Oncology
13.4.2.1.Breast Cancer
13.4.2.2.Prostate Cancer
13.4.2.3.Colorectal Cancer
13.4.2.4.Cervical Cancer
13.4.2.5.Kidney Cancer
13.4.2.6.Liver Cancer
13.4.2.7.Blood Cancer
13.4.2.8.Lung Cancer
13.4.2.9.Others
13.4.3.Pharamacogenomics
13.4.4.Hematopathology
13.4.5.Genetic Testing
13.4.6.Neurological Diseases
13.4.7.Cardiovascular Diseases
13.4.8.Others
13.5.Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1.Clinical Laboratories
13.5.2.Pharmaceutical and Biotechnology Companies
13.5.3.Research Institutions
13.6.Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1.France
13.6.1.1.France Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.1.1.1.Instruments
13.6.1.1.2.Solutions
13.6.1.1.3.Reagents and Kits
13.6.1.2.France Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.1.2.1.Polymerase chain reaction (PCR)
13.6.1.2.2.Nucleic Acid Amplification Tests (NAATs)
13.6.1.2.3.Next-generation sequencing (NGS)
13.6.1.2.4.Fluorescence In situ hybridization
13.6.1.2.5.Microarray Technology
13.6.1.2.6.CRISP-R
13.6.1.2.7.Others
13.6.1.3.France Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.1.3.1.Infectious diseases
13.6.1.3.1.1.Meningitis
13.6.1.3.1.2.Chlamydia
13.6.1.3.1.3.Gonorrhea
13.6.1.3.1.4.HIV
13.6.1.3.1.5.Carbapenem-resistant Bacteria
13.6.1.3.1.6.Flu
13.6.1.3.1.7.Respiratory Syncytial Virus (RSV)
13.6.1.3.1.8.Candida
13.6.1.3.1.9.Others
13.6.1.3.2.Oncology
13.6.1.3.2.1.Breast Cancer
13.6.1.3.2.2.Prostate Cancer
13.6.1.3.2.3.Colorectal Cancer
13.6.1.3.2.4.Cervical Cancer
13.6.1.3.2.5.Kidney Cancer
13.6.1.3.2.6.Liver Cancer
13.6.1.3.2.7.Blood Cancer
13.6.1.3.2.8.Lung Cancer
13.6.1.3.2.9.Others
13.6.1.3.3.Pharamacogenomics
13.6.1.3.4.Hematopathology
13.6.1.3.5.Genetic Testing
13.6.1.3.6.Neurological Diseases
13.6.1.3.7.Cardiovascular Diseases
13.6.1.3.8.Others
13.6.1.4.France Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.1.4.1.Clinical Laboratories
13.6.1.4.2.Pharmaceutical and Biotechnology Companies
13.6.1.4.3.Research Institutions
13.6.2.The UK
13.6.2.1.The UK Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.2.1.1.Instruments
13.6.2.1.2.Solutions
13.6.2.1.3.Reagents and Kits
13.6.2.2.The UK Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.2.2.1.Polymerase chain reaction (PCR)
13.6.2.2.2.Nucleic Acid Amplification Tests (NAATs)
13.6.2.2.3.Next-generation sequencing (NGS)
13.6.2.2.4.Fluorescence In situ hybridization
13.6.2.2.5.Microarray Technology
13.6.2.2.6.CRISP-R
13.6.2.2.7.Others
13.6.2.3.The UK Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.2.3.1.Infectious diseases
13.6.2.3.1.1.Meningitis
13.6.2.3.1.2.Chlamydia
13.6.2.3.1.3.Gonorrhea
13.6.2.3.1.4.HIV
13.6.2.3.1.5.Carbapenem-resistant Bacteria
13.6.2.3.1.6.Flu
13.6.2.3.1.7.Respiratory Syncytial Virus (RSV)
13.6.2.3.1.8.Candida
13.6.2.3.1.9.Others
13.6.2.3.2.Oncology
13.6.2.3.2.1.Breast Cancer
13.6.2.3.2.2.Prostate Cancer
13.6.2.3.2.3.Colorectal Cancer
13.6.2.3.2.4.Cervical Cancer
13.6.2.3.2.5.Kidney Cancer
13.6.2.3.2.6.Liver Cancer
13.6.2.3.2.7.Blood Cancer
13.6.2.3.2.8.Lung Cancer
13.6.2.3.2.9.Others
13.6.2.3.3.Pharamacogenomics
13.6.2.3.4.Hematopathology
13.6.2.3.5.Genetic Testing
13.6.2.3.6.Neurological Diseases
13.6.2.3.7.Cardiovascular Diseases
13.6.2.3.8.Others
13.6.2.4.The UK Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.2.4.1.Clinical Laboratories
13.6.2.4.2.Pharmaceutical and Biotechnology Companies
13.6.2.4.3.Research Institutions
13.6.3.Spain
13.6.3.1.Spain Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.3.1.1.Instruments
13.6.3.1.2.Solutions
13.6.3.1.3.Reagents and Kits
13.6.3.2.Spain Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.3.2.1.Polymerase chain reaction (PCR)
13.6.3.2.2.Nucleic Acid Amplification Tests (NAATs)
13.6.3.2.3.Next-generation sequencing (NGS)
13.6.3.2.4.Fluorescence In situ hybridization
13.6.3.2.5.Microarray Technology
13.6.3.2.6.CRISP-R
13.6.3.2.7.Others
13.6.3.3.Spain Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.3.3.1.Infectious diseases
13.6.3.3.1.1.Meningitis
13.6.3.3.1.2.Chlamydia
13.6.3.3.1.3.Gonorrhea
13.6.3.3.1.4.HIV
13.6.3.3.1.5.Carbapenem-resistant Bacteria
13.6.3.3.1.6.Flu
13.6.3.3.1.7.Respiratory Syncytial Virus (RSV)
13.6.3.3.1.8.Candida
13.6.3.3.1.9.Others
13.6.3.3.2.Oncology
13.6.3.3.2.1.Breast Cancer
13.6.3.3.2.2.Prostate Cancer
13.6.3.3.2.3.Colorectal Cancer
13.6.3.3.2.4.Cervical Cancer
13.6.3.3.2.5.Kidney Cancer
13.6.3.3.2.6.Liver Cancer
13.6.3.3.2.7.Blood Cancer
13.6.3.3.2.8.Lung Cancer
13.6.3.3.2.9.Others
13.6.3.3.3.Pharamacogenomics
13.6.3.3.4.Hematopathology
13.6.3.3.5.Genetic Testing
13.6.3.3.6.Neurological Diseases
13.6.3.3.7.Cardiovascular Diseases
13.6.3.3.8.Others
13.6.3.4.Spain Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.3.4.1.Clinical Laboratories
13.6.3.4.2.Pharmaceutical and Biotechnology Companies
13.6.3.4.3.Research Institutions
13.6.4.Germany
13.6.4.1.Germany Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.4.1.1.Instruments
13.6.4.1.2.Solutions
13.6.4.1.3.Reagents and Kits
13.6.4.2.Germany Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.4.2.1.Polymerase chain reaction (PCR)
13.6.4.2.2.Nucleic Acid Amplification Tests (NAATs)
13.6.4.2.3.Next-generation sequencing (NGS)
13.6.4.2.4.Fluorescence In situ hybridization
13.6.4.2.5.Microarray Technology
13.6.4.2.6.CRISP-R
13.6.4.2.7.Others
13.6.4.3.Germany Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.4.3.1.Infectious diseases
13.6.4.3.1.1.Meningitis
13.6.4.3.1.2.Chlamydia
13.6.4.3.1.3.Gonorrhea
13.6.4.3.1.4.HIV
13.6.4.3.1.5.Carbapenem-resistant Bacteria
13.6.4.3.1.6.Flu
13.6.4.3.1.7.Respiratory Syncytial Virus (RSV)
13.6.4.3.1.8.Candida
13.6.4.3.1.9.Others
13.6.4.3.2.Oncology
13.6.4.3.2.1.Breast Cancer
13.6.4.3.2.2.Prostate Cancer
13.6.4.3.2.3.Colorectal Cancer
13.6.4.3.2.4.Cervical Cancer
13.6.4.3.2.5.Kidney Cancer
13.6.4.3.2.6.Liver Cancer
13.6.4.3.2.7.Blood Cancer
13.6.4.3.2.8.Lung Cancer
13.6.4.3.2.9.Others
13.6.4.3.3.Pharamacogenomics
13.6.4.3.4.Hematopathology
13.6.4.3.5.Genetic Testing
13.6.4.3.6.Neurological Diseases
13.6.4.3.7.Cardiovascular Diseases
13.6.4.3.8.Others
13.6.4.4.Germany Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.4.4.1.Clinical Laboratories
13.6.4.4.2.Pharmaceutical and Biotechnology Companies
13.6.4.4.3.Research Institutions
13.6.5.Italy
13.6.5.1.Italy Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.5.1.1.Instruments
13.6.5.1.2.Solutions
13.6.5.1.3.Reagents and Kits
13.6.5.2.Italy Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.5.2.1.Polymerase chain reaction (PCR)
13.6.5.2.2.Nucleic Acid Amplification Tests (NAATs)
13.6.5.2.3.Next-generation sequencing (NGS)
13.6.5.2.4.Fluorescence In situ hybridization
13.6.5.2.5.Microarray Technology
13.6.5.2.6.CRISP-R
13.6.5.2.7.Others
13.6.5.3.Italy Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.5.3.1.Infectious diseases
13.6.5.3.1.1.Meningitis
13.6.5.3.1.2.Chlamydia
13.6.5.3.1.3.Gonorrhea
13.6.5.3.1.4.HIV
13.6.5.3.1.5.Carbapenem-resistant Bacteria
13.6.5.3.1.6.Flu
13.6.5.3.1.7.Respiratory Syncytial Virus (RSV)
13.6.5.3.1.8.Candida
13.6.5.3.1.9.Others
13.6.5.3.2.Oncology
13.6.5.3.2.1.Breast Cancer
13.6.5.3.2.2.Prostate Cancer
13.6.5.3.2.3.Colorectal Cancer
13.6.5.3.2.4.Cervical Cancer
13.6.5.3.2.5.Kidney Cancer
13.6.5.3.2.6.Liver Cancer
13.6.5.3.2.7.Blood Cancer
13.6.5.3.2.8.Lung Cancer
13.6.5.3.2.9.Others
13.6.5.3.3.Pharamacogenomics
13.6.5.3.4.Hematopathology
13.6.5.3.5.Genetic Testing
13.6.5.3.6.Neurological Diseases
13.6.5.3.7.Cardiovascular Diseases
13.6.5.3.8.Others
13.6.5.4.Italy Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.5.4.1.Clinical Laboratories
13.6.5.4.2.Pharmaceutical and Biotechnology Companies
13.6.5.4.3.Research Institutions
13.6.6.Nordic Countries
13.6.6.1.Nordic Countries Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.6.1.1.Instruments
13.6.6.1.2.Solutions
13.6.6.1.3.Reagents and Kits
13.6.6.2.Nordic Countries Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.6.2.1.Polymerase chain reaction (PCR)
13.6.6.2.2.Nucleic Acid Amplification Tests (NAATs)
13.6.6.2.3.Next-generation sequencing (NGS)
13.6.6.2.4.Fluorescence In situ hybridization
13.6.6.2.5.Microarray Technology
13.6.6.2.6.CRISP-R
13.6.6.2.7.Others
13.6.6.3.Nordic Countries Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.6.3.1.Infectious diseases
13.6.6.3.1.1.Meningitis
13.6.6.3.1.2.Chlamydia
13.6.6.3.1.3.Gonorrhea
13.6.6.3.1.4.HIV
13.6.6.3.1.5.Carbapenem-resistant Bacteria
13.6.6.3.1.6.Flu
13.6.6.3.1.7.Respiratory Syncytial Virus (RSV)
13.6.6.3.1.8.Candida
13.6.6.3.1.9.Others
13.6.6.3.2.Oncology
13.6.6.3.2.1.Breast Cancer
13.6.6.3.2.2.Prostate Cancer
13.6.6.3.2.3.Colorectal Cancer
13.6.6.3.2.4.Cervical Cancer
13.6.6.3.2.5.Kidney Cancer
13.6.6.3.2.6.Liver Cancer
13.6.6.3.2.7.Blood Cancer
13.6.6.3.2.8.Lung Cancer
13.6.6.3.2.9.Others
13.6.6.3.3.Pharamacogenomics
13.6.6.3.4.Hematopathology
13.6.6.3.5.Genetic Testing
13.6.6.3.6.Neurological Diseases
13.6.6.3.7.Cardiovascular Diseases
13.6.6.3.8.Others
13.6.6.4.Nordic Countries Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.6.4.1.Clinical Laboratories
13.6.6.4.2.Pharmaceutical and Biotechnology Companies
13.6.6.4.3.Research Institutions
13.6.6.5.Nordic Countries Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.6.6.5.1.Denmark
13.6.6.5.2.Finland
13.6.6.5.3.Iceland
13.6.6.5.4.Sweden
13.6.6.5.5.Norway
13.6.7.Benelux Union
13.6.7.1.Benelux Union Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.7.1.1.Instruments
13.6.7.1.2.Solutions
13.6.7.1.3.Reagents and Kits
13.6.7.2.Benelux Union Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.7.2.1.Polymerase chain reaction (PCR)
13.6.7.2.2.Nucleic Acid Amplification Tests (NAATs)
13.6.7.2.3.Next-generation sequencing (NGS)
13.6.7.2.4.Fluorescence In situ hybridization
13.6.7.2.5.Microarray Technology
13.6.7.2.6.CRISP-R
13.6.7.2.7.Others
13.6.7.3.Benelux Union Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.7.3.1.Infectious diseases
13.6.7.3.1.1.Meningitis
13.6.7.3.1.2.Chlamydia
13.6.7.3.1.3.Gonorrhea
13.6.7.3.1.4.HIV
13.6.7.3.1.5.Carbapenem-resistant Bacteria
13.6.7.3.1.6.Flu
13.6.7.3.1.7.Respiratory Syncytial Virus (RSV)
13.6.7.3.1.8.Candida
13.6.7.3.1.9.Others
13.6.7.3.2.Oncology
13.6.7.3.2.1.Breast Cancer
13.6.7.3.2.2.Prostate Cancer
13.6.7.3.2.3.Colorectal Cancer
13.6.7.3.2.4.Cervical Cancer
13.6.7.3.2.5.Kidney Cancer
13.6.7.3.2.6.Liver Cancer
13.6.7.3.2.7.Blood Cancer
13.6.7.3.2.8.Lung Cancer
13.6.7.3.2.9.Others
13.6.7.3.3.Pharamacogenomics
13.6.7.3.4.Hematopathology
13.6.7.3.5.Genetic Testing
13.6.7.3.6.Neurological Diseases
13.6.7.3.7.Cardiovascular Diseases
13.6.7.3.8.Others
13.6.7.4.Benelux Union Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.7.4.1.Clinical Laboratories
13.6.7.4.2.Pharmaceutical and Biotechnology Companies
13.6.7.4.3.Research Institutions
13.6.7.5.Benelux Union Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.6.7.5.1.Belgium
13.6.7.5.2.The Netherlands
13.6.7.5.3.Luxembourg
13.6.8.Rest of Europe
13.6.8.1.Rest of Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
13.6.8.1.1.Instruments
13.6.8.1.2.Solutions
13.6.8.1.3.Reagents and Kits
13.6.8.2.Rest of Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
13.6.8.2.1.Polymerase chain reaction (PCR)
13.6.8.2.2.Nucleic Acid Amplification Tests (NAATs)
13.6.8.2.3.Next-generation sequencing (NGS)
13.6.8.2.4.Fluorescence In situ hybridization
13.6.8.2.5.Microarray Technology
13.6.8.2.6.CRISP-R
13.6.8.2.7.Others
13.6.8.3.Rest of Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
13.6.8.3.1.Infectious diseases
13.6.8.3.1.1.Meningitis
13.6.8.3.1.2.Chlamydia
13.6.8.3.1.3.Gonorrhea
13.6.8.3.1.4.HIV
13.6.8.3.1.5.Carbapenem-resistant Bacteria
13.6.8.3.1.6.Flu
13.6.8.3.1.7.Respiratory Syncytial Virus (RSV)
13.6.8.3.1.8.Candida
13.6.8.3.1.9.Others
13.6.8.3.2.Oncology
13.6.8.3.2.1.Breast Cancer
13.6.8.3.2.2.Prostate Cancer
13.6.8.3.2.3.Colorectal Cancer
13.6.8.3.2.4.Cervical Cancer
13.6.8.3.2.5.Kidney Cancer
13.6.8.3.2.6.Liver Cancer
13.6.8.3.2.7.Blood Cancer
13.6.8.3.2.8.Lung Cancer
13.6.8.3.2.9.Others
13.6.8.3.3.Pharamacogenomics
13.6.8.3.4.Hematopathology
13.6.8.3.5.Genetic Testing
13.6.8.3.6.Neurological Diseases
13.6.8.3.7.Cardiovascular Diseases
13.6.8.3.8.Others
13.6.8.4.Rest of Europe Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.8.4.1.Clinical Laboratories
13.6.8.4.2.Pharmaceutical and Biotechnology Companies
13.6.8.4.3.Research Institutions
13.7.Key Segment for Channeling Investments
13.7.1.By Country
13.7.2.By Offerings
13.7.3.By Technology
13.7.4.By Application
13.7.5.By End Users
14.Asia Pacific Molecular Diagnostics Market Analysis and Forecasts, 2023 – 2031
14.1.Overview
14.1.1.Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn)
14.2.Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
14.2.1.Instruments
14.2.2.Solutions
14.2.3.Reagents and Kits
14.3.Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.3.1.Polymerase chain reaction (PCR)
14.3.2.Nucleic Acid Amplification Tests (NAATs)
14.3.3.Next-generation sequencing (NGS)
14.3.4.Fluorescence In situ hybridization
14.3.5.Microarray Technology
14.3.6.CRISP-R
14.3.7.Others
14.4.Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.4.1.Infectious diseases
14.4.1.1.Meningitis
14.4.1.2.Chlamydia
14.4.1.3.Gonorrhea
14.4.1.4.HIV
14.4.1.5.Carbapenem-resistant Bacteria
14.4.1.6.Flu
14.4.1.7.Respiratory Syncytial Virus (RSV)
14.4.1.8.Candida
14.4.1.9.Others
14.4.2.Oncology
14.4.2.1.Breast Cancer
14.4.2.2.Prostate Cancer
14.4.2.3.Colorectal Cancer
14.4.2.4.Cervical Cancer
14.4.2.5.Kidney Cancer
14.4.2.6.Liver Cancer
14.4.2.7.Blood Cancer
14.4.2.8.Lung Cancer
14.4.2.9.Others
14.4.3.Pharamacogenomics
14.4.4.Hematopathology
14.4.5.Genetic Testing
14.4.6.Neurological Diseases
14.4.7.Cardiovascular Diseases
14.4.8.Others
14.5.Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.1.Clinical Laboratories
14.5.2.Pharmaceutical and Biotechnology Companies
14.5.3.Research Institutions
14.6.Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1.China
14.6.1.1.China Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.1.1.1.Instruments
14.6.1.1.2.Solutions
14.6.1.1.3.Reagents and Kits
14.6.1.2.China Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.1.2.1.Polymerase chain reaction (PCR)
14.6.1.2.2.Nucleic Acid Amplification Tests (NAATs)
14.6.1.2.3.Next-generation sequencing (NGS)
14.6.1.2.4.Fluorescence In situ hybridization
14.6.1.2.5.Microarray Technology
14.6.1.2.6.CRISP-R
14.6.1.2.7.Others
14.6.1.3.China Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.1.3.1.Infectious diseases
14.6.1.3.1.1.Meningitis
14.6.1.3.1.2.Chlamydia
14.6.1.3.1.3.Gonorrhea
14.6.1.3.1.4.HIV
14.6.1.3.1.5.Carbapenem-resistant Bacteria
14.6.1.3.1.6.Flu
14.6.1.3.1.7.Respiratory Syncytial Virus (RSV)
14.6.1.3.1.8.Candida
14.6.1.3.1.9.Others
14.6.1.3.2.Oncology
14.6.1.3.2.1.Breast Cancer
14.6.1.3.2.2.Prostate Cancer
14.6.1.3.2.3.Colorectal Cancer
14.6.1.3.2.4.Cervical Cancer
14.6.1.3.2.5.Kidney Cancer
14.6.1.3.2.6.Liver Cancer
14.6.1.3.2.7.Blood Cancer
14.6.1.3.2.8.Lung Cancer
14.6.1.3.2.9.Others
14.6.1.3.3.Pharamacogenomics
14.6.1.3.4.Hematopathology
14.6.1.3.5.Genetic Testing
14.6.1.3.6.Neurological Diseases
14.6.1.3.7.Cardiovascular Diseases
14.6.1.3.8.Others
14.6.1.4.China Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.1.4.1.Clinical Laboratories
14.6.1.4.2.Pharmaceutical and Biotechnology Companies
14.6.1.4.3.Research Institutions
14.6.2.Japan
14.6.2.1.Japan Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.2.1.1.Instruments
14.6.2.1.2.Solutions
14.6.2.1.3.Reagents and Kits
14.6.2.2.Japan Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.2.2.1.Polymerase chain reaction (PCR)
14.6.2.2.2.Nucleic Acid Amplification Tests (NAATs)
14.6.2.2.3.Next-generation sequencing (NGS)
14.6.2.2.4.Fluorescence In situ hybridization
14.6.2.2.5.Microarray Technology
14.6.2.2.6.CRISP-R
14.6.2.2.7.Others
14.6.2.3.Japan Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.2.3.1.Infectious diseases
14.6.2.3.1.1.Meningitis
14.6.2.3.1.2.Chlamydia
14.6.2.3.1.3.Gonorrhea
14.6.2.3.1.4.HIV
14.6.2.3.1.5.Carbapenem-resistant Bacteria
14.6.2.3.1.6.Flu
14.6.2.3.1.7.Respiratory Syncytial Virus (RSV)
14.6.2.3.1.8.Candida
14.6.2.3.1.9.Others
14.6.2.3.2.Oncology
14.6.2.3.2.1.Breast Cancer
14.6.2.3.2.2.Prostate Cancer
14.6.2.3.2.3.Colorectal Cancer
14.6.2.3.2.4.Cervical Cancer
14.6.2.3.2.5.Kidney Cancer
14.6.2.3.2.6.Liver Cancer
14.6.2.3.2.7.Blood Cancer
14.6.2.3.2.8.Lung Cancer
14.6.2.3.2.9.Others
14.6.2.3.3.Pharamacogenomics
14.6.2.3.4.Hematopathology
14.6.2.3.5.Genetic Testing
14.6.2.3.6.Neurological Diseases
14.6.2.3.7.Cardiovascular Diseases
14.6.2.3.8.Others
14.6.2.4.Japan Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.2.4.1.Clinical Laboratories
14.6.2.4.2.Pharmaceutical and Biotechnology Companies
14.6.2.4.3.Research Institutions
14.6.3.India
14.6.3.1.India Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.3.1.1.Instruments
14.6.3.1.2.Solutions
14.6.3.1.3.Reagents and Kits
14.6.3.2.India Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.3.2.1.Polymerase chain reaction (PCR)
14.6.3.2.2.Nucleic Acid Amplification Tests (NAATs)
14.6.3.2.3.Next-generation sequencing (NGS)
14.6.3.2.4.Fluorescence In situ hybridization
14.6.3.2.5.Microarray Technology
14.6.3.2.6.CRISP-R
14.6.3.2.7.Others
14.6.3.3.India Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.3.3.1.Infectious diseases
14.6.3.3.1.1.Meningitis
14.6.3.3.1.2.Chlamydia
14.6.3.3.1.3.Gonorrhea
14.6.3.3.1.4.HIV
14.6.3.3.1.5.Carbapenem-resistant Bacteria
14.6.3.3.1.6.Flu
14.6.3.3.1.7.Respiratory Syncytial Virus (RSV)
14.6.3.3.1.8.Candida
14.6.3.3.1.9.Others
14.6.3.3.2.Oncology
14.6.3.3.2.1.Breast Cancer
14.6.3.3.2.2.Prostate Cancer
14.6.3.3.2.3.Colorectal Cancer
14.6.3.3.2.4.Cervical Cancer
14.6.3.3.2.5.Kidney Cancer
14.6.3.3.2.6.Liver Cancer
14.6.3.3.2.7.Blood Cancer
14.6.3.3.2.8.Lung Cancer
14.6.3.3.2.9.Others
14.6.3.3.3.Pharamacogenomics
14.6.3.3.4.Hematopathology
14.6.3.3.5.Genetic Testing
14.6.3.3.6.Neurological Diseases
14.6.3.3.7.Cardiovascular Diseases
14.6.3.3.8.Others
14.6.3.4.India Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.3.4.1.Clinical Laboratories
14.6.3.4.2.Pharmaceutical and Biotechnology Companies
14.6.3.4.3.Research Institutions
14.6.4.New Zealand
14.6.4.1.New Zealand Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.4.1.1.Instruments
14.6.4.1.2.Solutions
14.6.4.1.3.Reagents and Kits
14.6.4.2.New Zealand Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.4.2.1.Polymerase chain reaction (PCR)
14.6.4.2.2.Nucleic Acid Amplification Tests (NAATs)
14.6.4.2.3.Next-generation sequencing (NGS)
14.6.4.2.4.Fluorescence In situ hybridization
14.6.4.2.5.Microarray Technology
14.6.4.2.6.CRISP-R
14.6.4.2.7.Others
14.6.4.3.New Zealand Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.4.3.1.Infectious diseases
14.6.4.3.1.1.Meningitis
14.6.4.3.1.2.Chlamydia
14.6.4.3.1.3.Gonorrhea
14.6.4.3.1.4.HIV
14.6.4.3.1.5.Carbapenem-resistant Bacteria
14.6.4.3.1.6.Flu
14.6.4.3.1.7.Respiratory Syncytial Virus (RSV)
14.6.4.3.1.8.Candida
14.6.4.3.1.9.Others
14.6.4.3.2.Oncology
14.6.4.3.2.1.Breast Cancer
14.6.4.3.2.2.Prostate Cancer
14.6.4.3.2.3.Colorectal Cancer
14.6.4.3.2.4.Cervical Cancer
14.6.4.3.2.5.Kidney Cancer
14.6.4.3.2.6.Liver Cancer
14.6.4.3.2.7.Blood Cancer
14.6.4.3.2.8.Lung Cancer
14.6.4.3.2.9.Others
14.6.4.3.3.Pharamacogenomics
14.6.4.3.4.Hematopathology
14.6.4.3.5.Genetic Testing
14.6.4.3.6.Neurological Diseases
14.6.4.3.7.Cardiovascular Diseases
14.6.4.3.8.Others
14.6.4.4.New Zealand Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.4.4.1.Clinical Laboratories
14.6.4.4.2.Pharmaceutical and Biotechnology Companies
14.6.4.4.3.Research Institutions
14.6.5.Australia
14.6.5.1.Australia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.5.1.1.Instruments
14.6.5.1.2.Solutions
14.6.5.1.3.Reagents and Kits
14.6.5.2.Australia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.5.2.1.Polymerase chain reaction (PCR)
14.6.5.2.2.Nucleic Acid Amplification Tests (NAATs)
14.6.5.2.3.Next-generation sequencing (NGS)
14.6.5.2.4.Fluorescence In situ hybridization
14.6.5.2.5.Microarray Technology
14.6.5.2.6.CRISP-R
14.6.5.2.7.Others
14.6.5.3.Australia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.5.3.1.Infectious diseases
14.6.5.3.1.1.Meningitis
14.6.5.3.1.2.Chlamydia
14.6.5.3.1.3.Gonorrhea
14.6.5.3.1.4.HIV
14.6.5.3.1.5.Carbapenem-resistant Bacteria
14.6.5.3.1.6.Flu
14.6.5.3.1.7.Respiratory Syncytial Virus (RSV)
14.6.5.3.1.8.Candida
14.6.5.3.1.9.Others
14.6.5.3.2.Oncology
14.6.5.3.2.1.Breast Cancer
14.6.5.3.2.2.Prostate Cancer
14.6.5.3.2.3.Colorectal Cancer
14.6.5.3.2.4.Cervical Cancer
14.6.5.3.2.5.Kidney Cancer
14.6.5.3.2.6.Liver Cancer
14.6.5.3.2.7.Blood Cancer
14.6.5.3.2.8.Lung Cancer
14.6.5.3.2.9.Others
14.6.5.3.3.Pharamacogenomics
14.6.5.3.4.Hematopathology
14.6.5.3.5.Genetic Testing
14.6.5.3.6.Neurological Diseases
14.6.5.3.7.Cardiovascular Diseases
14.6.5.3.8.Others
14.6.5.4.Australia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.5.4.1.Clinical Laboratories
14.6.5.4.2.Pharmaceutical and Biotechnology Companies
14.6.5.4.3.Research Institutions
14.6.6.South Korea
14.6.6.1.South Korea Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.6.1.1.Instruments
14.6.6.1.2.Solutions
14.6.6.1.3.Reagents and Kits
14.6.6.2.South Korea Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.6.2.1.Polymerase chain reaction (PCR)
14.6.6.2.2.Nucleic Acid Amplification Tests (NAATs)
14.6.6.2.3.Next-generation sequencing (NGS)
14.6.6.2.4.Fluorescence In situ hybridization
14.6.6.2.5.Microarray Technology
14.6.6.2.6.CRISP-R
14.6.6.2.7.Others
14.6.6.3.South Korea Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.6.3.1.Infectious diseases
14.6.6.3.1.1.Meningitis
14.6.6.3.1.2.Chlamydia
14.6.6.3.1.3.Gonorrhea
14.6.6.3.1.4.HIV
14.6.6.3.1.5.Carbapenem-resistant Bacteria
14.6.6.3.1.6.Flu
14.6.6.3.1.7.Respiratory Syncytial Virus (RSV)
14.6.6.3.1.8.Candida
14.6.6.3.1.9.Others
14.6.6.3.2.Oncology
14.6.6.3.2.1.Breast Cancer
14.6.6.3.2.2.Prostate Cancer
14.6.6.3.2.3.Colorectal Cancer
14.6.6.3.2.4.Cervical Cancer
14.6.6.3.2.5.Kidney Cancer
14.6.6.3.2.6.Liver Cancer
14.6.6.3.2.7.Blood Cancer
14.6.6.3.2.8.Lung Cancer
14.6.6.3.2.9.Others
14.6.6.3.3.Pharamacogenomics
14.6.6.3.4.Hematopathology
14.6.6.3.5.Genetic Testing
14.6.6.3.6.Neurological Diseases
14.6.6.3.7.Cardiovascular Diseases
14.6.6.3.8.Others
14.6.6.4.South Korea Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.6.4.1.Clinical Laboratories
14.6.6.4.2.Pharmaceutical and Biotechnology Companies
14.6.6.4.3.Research Institutions
14.6.7.Southeast Asia
14.6.7.1.Southeast Asia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.7.1.1.Instruments
14.6.7.1.2.Solutions
14.6.7.1.3.Reagents and Kits
14.6.7.2.Southeast Asia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.7.2.1.Polymerase chain reaction (PCR)
14.6.7.2.2.Nucleic Acid Amplification Tests (NAATs)
14.6.7.2.3.Next-generation sequencing (NGS)
14.6.7.2.4.Fluorescence In situ hybridization
14.6.7.2.5.Microarray Technology
14.6.7.2.6.CRISP-R
14.6.7.2.7.Others
14.6.7.3.Southeast Asia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.7.3.1.Infectious diseases
14.6.7.3.1.1.Meningitis
14.6.7.3.1.2.Chlamydia
14.6.7.3.1.3.Gonorrhea
14.6.7.3.1.4.HIV
14.6.7.3.1.5.Carbapenem-resistant Bacteria
14.6.7.3.1.6.Flu
14.6.7.3.1.7.Respiratory Syncytial Virus (RSV)
14.6.7.3.1.8.Candida
14.6.7.3.1.9.Others
14.6.7.3.2.Oncology
14.6.7.3.2.1.Breast Cancer
14.6.7.3.2.2.Prostate Cancer
14.6.7.3.2.3.Colorectal Cancer
14.6.7.3.2.4.Cervical Cancer
14.6.7.3.2.5.Kidney Cancer
14.6.7.3.2.6.Liver Cancer
14.6.7.3.2.7.Blood Cancer
14.6.7.3.2.8.Lung Cancer
14.6.7.3.2.9.Others
14.6.7.3.3.Pharamacogenomics
14.6.7.3.4.Hematopathology
14.6.7.3.5.Genetic Testing
14.6.7.3.6.Neurological Diseases
14.6.7.3.7.Cardiovascular Diseases
14.6.7.3.8.Others
14.6.7.4.Southeast Asia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.7.4.1.Clinical Laboratories
14.6.7.4.2.Pharmaceutical and Biotechnology Companies
14.6.7.4.3.Research Institutions
14.6.7.5.Southeast Asia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
14.6.7.5.1.Indonesia
14.6.7.5.2.Thailand
14.6.7.5.3.Malaysia
14.6.7.5.4.Singapore
14.6.7.5.5.Rest of Southeast Asia
14.6.8.Rest of Asia Pacific
14.6.8.1.Rest of Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
14.6.8.1.1.Instruments
14.6.8.1.2.Solutions
14.6.8.1.3.Reagents and Kits
14.6.8.2.Rest of Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
14.6.8.2.1.Polymerase chain reaction (PCR)
14.6.8.2.2.Nucleic Acid Amplification Tests (NAATs)
14.6.8.2.3.Next-generation sequencing (NGS)
14.6.8.2.4.Fluorescence In situ hybridization
14.6.8.2.5.Microarray Technology
14.6.8.2.6.CRISP-R
14.6.8.2.7.Others
14.6.8.3.Rest of Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
14.6.8.3.1.Infectious diseases
14.6.8.3.1.1.Meningitis
14.6.8.3.1.2.Chlamydia
14.6.8.3.1.3.Gonorrhea
14.6.8.3.1.4.HIV
14.6.8.3.1.5.Carbapenem-resistant Bacteria
14.6.8.3.1.6.Flu
14.6.8.3.1.7.Respiratory Syncytial Virus (RSV)
14.6.8.3.1.8.Candida
14.6.8.3.1.9.Others
14.6.8.3.2.Oncology
14.6.8.3.2.1.Breast Cancer
14.6.8.3.2.2.Prostate Cancer
14.6.8.3.2.3.Colorectal Cancer
14.6.8.3.2.4.Cervical Cancer
14.6.8.3.2.5.Kidney Cancer
14.6.8.3.2.6.Liver Cancer
14.6.8.3.2.7.Blood Cancer
14.6.8.3.2.8.Lung Cancer
14.6.8.3.2.9.Others
14.6.8.3.3.Pharamacogenomics
14.6.8.3.4.Hematopathology
14.6.8.3.5.Genetic Testing
14.6.8.3.6.Neurological Diseases
14.6.8.3.7.Cardiovascular Diseases
14.6.8.3.8.Others
14.6.8.4.Rest of Asia Pacific Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.8.4.1.Clinical Laboratories
14.6.8.4.2.Pharmaceutical and Biotechnology Companies
14.6.8.4.3.Research Institutions
14.7.Key Segment for Channeling Investments
14.7.1.By Country
14.7.2.By Offerings
14.7.3.By Technology
14.7.4.By Application
14.7.5.By End Users
15.Middle East and Africa Molecular Diagnostics Market Analysis and Forecasts, 2023 – 2031
15.1.Overview
15.1.1.Middle East and Africa Molecular Diagnostics Market Revenue (US$ Mn)
15.2.Middle East and Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
15.2.1.Instruments
15.2.2.Solutions
15.2.3.Reagents and Kits
15.3.Middle East and Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
15.3.1.Polymerase chain reaction (PCR)
15.3.2.Nucleic Acid Amplification Tests (NAATs)
15.3.3.Next-generation sequencing (NGS)
15.3.4.Fluorescence In situ hybridization
15.3.5.Microarray Technology
15.3.6.CRISP-R
15.3.7.Others
15.4.Middle East and Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.4.1.Infectious diseases
15.4.1.1.Meningitis
15.4.1.2.Chlamydia
15.4.1.3.Gonorrhea
15.4.1.4.HIV
15.4.1.5.Carbapenem-resistant Bacteria
15.4.1.6.Flu
15.4.1.7.Respiratory Syncytial Virus (RSV)
15.4.1.8.Candida
15.4.1.9.Others
15.4.2.Oncology
15.4.2.1.Breast Cancer
15.4.2.2.Prostate Cancer
15.4.2.3.Colorectal Cancer
15.4.2.4.Cervical Cancer
15.4.2.5.Kidney Cancer
15.4.2.6.Liver Cancer
15.4.2.7.Blood Cancer
15.4.2.8.Lung Cancer
15.4.2.9.Others
15.4.3.Pharamacogenomics
15.4.4.Hematopathology
15.4.5.Genetic Testing
15.4.6.Neurological Diseases
15.4.7.Cardiovascular Diseases
15.4.8.Others
15.5.Middle East and Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.1.Clinical Laboratories
15.5.2.Pharmaceutical and Biotechnology Companies
15.5.3.Research Institutions
15.6.Middle East and Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
15.6.1.Saudi Arabia
15.6.1.1.Saudi Arabia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.1.1.1.Instruments
15.6.1.1.2.Solutions
15.6.1.1.3.Reagents and Kits
15.6.1.2.Saudi Arabia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
15.6.1.2.1.Polymerase chain reaction (PCR)
15.6.1.2.2.Nucleic Acid Amplification Tests (NAATs)
15.6.1.2.3.Next-generation sequencing (NGS)
15.6.1.2.4.Fluorescence In situ hybridization
15.6.1.2.5.Microarray Technology
15.6.1.2.6.CRISP-R
15.6.1.2.7.Others
15.6.1.3.Saudi Arabia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.6.1.3.1.Infectious diseases
15.6.1.3.1.1.Meningitis
15.6.1.3.1.2.Chlamydia
15.6.1.3.1.3.Gonorrhea
15.6.1.3.1.4.HIV
15.6.1.3.1.5.Carbapenem-resistant Bacteria
15.6.1.3.1.6.Flu
15.6.1.3.1.7.Respiratory Syncytial Virus (RSV)
15.6.1.3.1.8.Candida
15.6.1.3.1.9.Others
15.6.1.3.2.Oncology
15.6.1.3.2.1.Breast Cancer
15.6.1.3.2.2.Prostate Cancer
15.6.1.3.2.3.Colorectal Cancer
15.6.1.3.2.4.Cervical Cancer
15.6.1.3.2.5.Kidney Cancer
15.6.1.3.2.6.Liver Cancer
15.6.1.3.2.7.Blood Cancer
15.6.1.3.2.8.Lung Cancer
15.6.1.3.2.9.Others
15.6.1.3.3.Pharamacogenomics
15.6.1.3.4.Hematopathology
15.6.1.3.5.Genetic Testing
15.6.1.3.6.Neurological Diseases
15.6.1.3.7.Cardiovascular Diseases
15.6.1.3.8.Others
15.6.1.4.Saudi Arabia Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.1.4.1.Clinical Laboratories
15.6.1.4.2.Pharmaceutical and Biotechnology Companies
15.6.1.4.3.Research Institutions
15.6.2.UAE
15.6.2.1.UAE Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.2.1.1.Instruments
15.6.2.1.2.Solutions
15.6.2.1.3.Reagents and Kits
15.6.2.2.UAE Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
15.6.2.2.1.Polymerase chain reaction (PCR)
15.6.2.2.2.Nucleic Acid Amplification Tests (NAATs)
15.6.2.2.3.Next-generation sequencing (NGS)
15.6.2.2.4.Fluorescence In situ hybridization
15.6.2.2.5.Microarray Technology
15.6.2.2.6.CRISP-R
15.6.2.2.7.Others
15.6.2.3.UAE Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.6.2.3.1.Infectious diseases
15.6.2.3.1.1.Meningitis
15.6.2.3.1.2.Chlamydia
15.6.2.3.1.3.Gonorrhea
15.6.2.3.1.4.HIV
15.6.2.3.1.5.Carbapenem-resistant Bacteria
15.6.2.3.1.6.Flu
15.6.2.3.1.7.Respiratory Syncytial Virus (RSV)
15.6.2.3.1.8.Candida
15.6.2.3.1.9.Others
15.6.2.3.2.Oncology
15.6.2.3.2.1.Breast Cancer
15.6.2.3.2.2.Prostate Cancer
15.6.2.3.2.3.Colorectal Cancer
15.6.2.3.2.4.Cervical Cancer
15.6.2.3.2.5.Kidney Cancer
15.6.2.3.2.6.Liver Cancer
15.6.2.3.2.7.Blood Cancer
15.6.2.3.2.8.Lung Cancer
15.6.2.3.2.9.Others
15.6.2.3.3.Pharamacogenomics
15.6.2.3.4.Hematopathology
15.6.2.3.5.Genetic Testing
15.6.2.3.6.Neurological Diseases
15.6.2.3.7.Cardiovascular Diseases
15.6.2.3.8.Others
15.6.2.4.UAE Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.2.4.1.Clinical Laboratories
15.6.2.4.2.Pharmaceutical and Biotechnology Companies
15.6.2.4.3.Research Institutions
15.6.3.Egypt
15.6.3.1.Egypt Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.3.1.1.Instruments
15.6.3.1.2.Solutions
15.6.3.1.3.Reagents and Kits
15.6.3.2.Egypt Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
15.6.3.2.1.Polymerase chain reaction (PCR)
15.6.3.2.2.Nucleic Acid Amplification Tests (NAATs)
15.6.3.2.3.Next-generation sequencing (NGS)
15.6.3.2.4.Fluorescence In situ hybridization
15.6.3.2.5.Microarray Technology
15.6.3.2.6.CRISP-R
15.6.3.2.7.Others
15.6.3.3.Egypt Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.6.3.3.1.Infectious diseases
15.6.3.3.1.1.Meningitis
15.6.3.3.1.2.Chlamydia
15.6.3.3.1.3.Gonorrhea
15.6.3.3.1.4.HIV
15.6.3.3.1.5.Carbapenem-resistant Bacteria
15.6.3.3.1.6.Flu
15.6.3.3.1.7.Respiratory Syncytial Virus (RSV)
15.6.3.3.1.8.Candida
15.6.3.3.1.9.Others
15.6.3.3.2.Oncology
15.6.3.3.2.1.Breast Cancer
15.6.3.3.2.2.Prostate Cancer
15.6.3.3.2.3.Colorectal Cancer
15.6.3.3.2.4.Cervical Cancer
15.6.3.3.2.5.Kidney Cancer
15.6.3.3.2.6.Liver Cancer
15.6.3.3.2.7.Blood Cancer
15.6.3.3.2.8.Lung Cancer
15.6.3.3.2.9.Others
15.6.3.3.3.Pharamacogenomics
15.6.3.3.4.Hematopathology
15.6.3.3.5.Genetic Testing
15.6.3.3.6.Neurological Diseases
15.6.3.3.7.Cardiovascular Diseases
15.6.3.3.8.Others
15.6.3.4.Egypt Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.3.4.1.Clinical Laboratories
15.6.3.4.2.Pharmaceutical and Biotechnology Companies
15.6.3.4.3.Research Institutions
15.6.4.Kuwait
15.6.4.1.Kuwait Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.4.1.1.Instruments
15.6.4.1.2.Solutions
15.6.4.1.3.Reagents and Kits
15.6.4.2.Kuwait Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
15.6.4.2.1.Polymerase chain reaction (PCR)
15.6.4.2.2.Nucleic Acid Amplification Tests (NAATs)
15.6.4.2.3.Next-generation sequencing (NGS)
15.6.4.2.4.Fluorescence In situ hybridization
15.6.4.2.5.Microarray Technology
15.6.4.2.6.CRISP-R
15.6.4.2.7.Others
15.6.4.3.Kuwait Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.6.4.3.1.Infectious diseases
15.6.4.3.1.1.Meningitis
15.6.4.3.1.2.Chlamydia
15.6.4.3.1.3.Gonorrhea
15.6.4.3.1.4.HIV
15.6.4.3.1.5.Carbapenem-resistant Bacteria
15.6.4.3.1.6.Flu
15.6.4.3.1.7.Respiratory Syncytial Virus (RSV)
15.6.4.3.1.8.Candida
15.6.4.3.1.9.Others
15.6.4.3.2.Oncology
15.6.4.3.2.1.Breast Cancer
15.6.4.3.2.2.Prostate Cancer
15.6.4.3.2.3.Colorectal Cancer
15.6.4.3.2.4.Cervical Cancer
15.6.4.3.2.5.Kidney Cancer
15.6.4.3.2.6.Liver Cancer
15.6.4.3.2.7.Blood Cancer
15.6.4.3.2.8.Lung Cancer
15.6.4.3.2.9.Others
15.6.4.3.3.Pharamacogenomics
15.6.4.3.4.Hematopathology
15.6.4.3.5.Genetic Testing
15.6.4.3.6.Neurological Diseases
15.6.4.3.7.Cardiovascular Diseases
15.6.4.3.8.Others
15.6.4.4.Kuwait Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.4.4.1.Clinical Laboratories
15.6.4.4.2.Pharmaceutical and Biotechnology Companies
15.6.4.4.3.Research Institutions
15.6.5.South Africa
15.6.5.1.South Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.5.1.1.Instruments
15.6.5.1.2.Solutions
15.6.5.1.3.Reagents and Kits
15.6.5.2.South Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
15.6.5.2.1.Polymerase chain reaction (PCR)
15.6.5.2.2.Nucleic Acid Amplification Tests (NAATs)
15.6.5.2.3.Next-generation sequencing (NGS)
15.6.5.2.4.Fluorescence In situ hybridization
15.6.5.2.5.Microarray Technology
15.6.5.2.6.CRISP-R
15.6.5.2.7.Others
15.6.5.3.South Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.6.5.3.1.Infectious diseases
15.6.5.3.1.1.Meningitis
15.6.5.3.1.2.Chlamydia
15.6.5.3.1.3.Gonorrhea
15.6.5.3.1.4.HIV
15.6.5.3.1.5.Carbapenem-resistant Bacteria
15.6.5.3.1.6.Flu
15.6.5.3.1.7.Respiratory Syncytial Virus (RSV)
15.6.5.3.1.8.Candida
15.6.5.3.1.9.Others
15.6.5.3.2.Oncology
15.6.5.3.2.1.Breast Cancer
15.6.5.3.2.2.Prostate Cancer
15.6.5.3.2.3.Colorectal Cancer
15.6.5.3.2.4.Cervical Cancer
15.6.5.3.2.5.Kidney Cancer
15.6.5.3.2.6.Liver Cancer
15.6.5.3.2.7.Blood Cancer
15.6.5.3.2.8.Lung Cancer
15.6.5.3.2.9.Others
15.6.5.3.3.Pharamacogenomics
15.6.5.3.4.Hematopathology
15.6.5.3.5.Genetic Testing
15.6.5.3.6.Neurological Diseases
15.6.5.3.7.Cardiovascular Diseases
15.6.5.3.8.Others
15.6.5.4.South Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.5.4.1.Clinical Laboratories
15.6.5.4.2.Pharmaceutical and Biotechnology Companies
15.6.5.4.3.Research Institutions
15.6.6.Rest of Middle East & Africa
15.6.6.1.Rest of Middle East & Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
15.6.6.1.1.Instruments
15.6.6.1.2.Solutions
15.6.6.1.3.Reagents and Kits
15.6.6.2.Rest of Middle East & Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
15.6.6.2.1.Polymerase chain reaction (PCR)
15.6.6.2.2.Nucleic Acid Amplification Tests (NAATs)
15.6.6.2.3.Next-generation sequencing (NGS)
15.6.6.2.4.Fluorescence In situ hybridization
15.6.6.2.5.Microarray Technology
15.6.6.2.6.CRISP-R
15.6.6.2.7.Others
15.6.6.3.Rest of Middle East & Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
15.6.6.3.1.Infectious diseases
15.6.6.3.1.1.Meningitis
15.6.6.3.1.2.Chlamydia
15.6.6.3.1.3.Gonorrhea
15.6.6.3.1.4.HIV
15.6.6.3.1.5.Carbapenem-resistant Bacteria
15.6.6.3.1.6.Flu
15.6.6.3.1.7.Respiratory Syncytial Virus (RSV)
15.6.6.3.1.8.Candida
15.6.6.3.1.9.Others
15.6.6.3.2.Oncology
15.6.6.3.2.1.Breast Cancer
15.6.6.3.2.2.Prostate Cancer
15.6.6.3.2.3.Colorectal Cancer
15.6.6.3.2.4.Cervical Cancer
15.6.6.3.2.5.Kidney Cancer
15.6.6.3.2.6.Liver Cancer
15.6.6.3.2.7.Blood Cancer
15.6.6.3.2.8.Lung Cancer
15.6.6.3.2.9.Others
15.6.6.3.3.Pharamacogenomics
15.6.6.3.4.Hematopathology
15.6.6.3.5.Genetic Testing
15.6.6.3.6.Neurological Diseases
15.6.6.3.7.Cardiovascular Diseases
15.6.6.3.8.Others
15.6.6.4.Rest of Middle East & Africa Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1.Clinical Laboratories
15.6.6.4.2.Pharmaceutical and Biotechnology Companies
15.6.6.4.3.Research Institutions
15.7.Key Segment for Channeling Investments
15.7.1.By Country
15.7.2.By Offerings
15.7.3.By Technology
15.7.4.By Application
15.7.5.By End Users
16.Latin America Molecular Diagnostics Market Analysis and Forecasts, 2023 – 2031
16.1.Overview
16.1.1.Latin America Molecular Diagnostics Market Revenue (US$ Mn)
16.2.Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
16.2.1.Instruments
16.2.2.Solutions
16.2.3.Reagents and Kits
16.3.Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
16.3.1.Polymerase chain reaction (PCR)
16.3.2.Nucleic Acid Amplification Tests (NAATs)
16.3.3.Next-generation sequencing (NGS)
16.3.4.Fluorescence In situ hybridization
16.3.5.Microarray Technology
16.3.6.CRISP-R
16.3.7.Others
16.4.Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
16.4.1.Infectious diseases
16.4.1.1.Meningitis
16.4.1.2.Chlamydia
16.4.1.3.Gonorrhea
16.4.1.4.HIV
16.4.1.5.Carbapenem-resistant Bacteria
16.4.1.6.Flu
16.4.1.7.Respiratory Syncytial Virus (RSV)
16.4.1.8.Candida
16.4.1.9.Others
16.4.2.Oncology
16.4.2.1.Breast Cancer
16.4.2.2.Prostate Cancer
16.4.2.3.Colorectal Cancer
16.4.2.4.Cervical Cancer
16.4.2.5.Kidney Cancer
16.4.2.6.Liver Cancer
16.4.2.7.Blood Cancer
16.4.2.8.Lung Cancer
16.4.2.9.Others
16.4.3.Pharamacogenomics
16.4.4.Hematopathology
16.4.5.Genetic Testing
16.4.6.Neurological Diseases
16.4.7.Cardiovascular Diseases
16.4.8.Others
16.5.Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
16.5.1.Clinical Laboratories
16.5.2.Pharmaceutical and Biotechnology Companies
16.5.3.Research Institutions
16.6.Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1.Brazil
16.6.1.1.Brazil Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
16.6.1.1.1.Instruments
16.6.1.1.2.Solutions
16.6.1.1.3.Reagents and Kits
16.6.1.2.Brazil Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
16.6.1.2.1.Polymerase chain reaction (PCR)
16.6.1.2.2.Nucleic Acid Amplification Tests (NAATs)
16.6.1.2.3.Next-generation sequencing (NGS)
16.6.1.2.4.Fluorescence In situ hybridization
16.6.1.2.5.Microarray Technology
16.6.1.2.6.CRISP-R
16.6.1.2.7.Others
16.6.1.3.Brazil Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
16.6.1.3.1.Infectious diseases
16.6.1.3.1.1.Meningitis
16.6.1.3.1.2.Chlamydia
16.6.1.3.1.3.Gonorrhea
16.6.1.3.1.4.HIV
16.6.1.3.1.5.Carbapenem-resistant Bacteria
16.6.1.3.1.6.Flu
16.6.1.3.1.7.Respiratory Syncytial Virus (RSV)
16.6.1.3.1.8.Candida
16.6.1.3.1.9.Others
16.6.1.3.2.Oncology
16.6.1.3.2.1.Breast Cancer
16.6.1.3.2.2.Prostate Cancer
16.6.1.3.2.3.Colorectal Cancer
16.6.1.3.2.4.Cervical Cancer
16.6.1.3.2.5.Kidney Cancer
16.6.1.3.2.6.Liver Cancer
16.6.1.3.2.7.Blood Cancer
16.6.1.3.2.8.Lung Cancer
16.6.1.3.2.9.Others
16.6.1.3.3.Pharamacogenomics
16.6.1.3.4.Hematopathology
16.6.1.3.5.Genetic Testing
16.6.1.3.6.Neurological Diseases
16.6.1.3.7.Cardiovascular Diseases
16.6.1.3.8.Others
16.6.1.4.Brazil Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.1.4.1.Clinical Laboratories
16.6.1.4.2.Pharmaceutical and Biotechnology Companies
16.6.1.4.3.Research Institutions
16.6.2.Argentina
16.6.2.1.Argentina Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
16.6.2.1.1.Instruments
16.6.2.1.2.Solutions
16.6.2.1.3.Reagents and Kits
16.6.2.2.Argentina Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
16.6.2.2.1.Polymerase chain reaction (PCR)
16.6.2.2.2.Nucleic Acid Amplification Tests (NAATs)
16.6.2.2.3.Next-generation sequencing (NGS)
16.6.2.2.4.Fluorescence In situ hybridization
16.6.2.2.5.Microarray Technology
16.6.2.2.6.CRISP-R
16.6.2.2.7.Others
16.6.2.3.Argentina Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
16.6.2.3.1.Infectious diseases
16.6.2.3.1.1.Meningitis
16.6.2.3.1.2.Chlamydia
16.6.2.3.1.3.Gonorrhea
16.6.2.3.1.4.HIV
16.6.2.3.1.5.Carbapenem-resistant Bacteria
16.6.2.3.1.6.Flu
16.6.2.3.1.7.Respiratory Syncytial Virus (RSV)
16.6.2.3.1.8.Candida
16.6.2.3.1.9.Others
16.6.2.3.2.Oncology
16.6.2.3.2.1.Breast Cancer
16.6.2.3.2.2.Prostate Cancer
16.6.2.3.2.3.Colorectal Cancer
16.6.2.3.2.4.Cervical Cancer
16.6.2.3.2.5.Kidney Cancer
16.6.2.3.2.6.Liver Cancer
16.6.2.3.2.7.Blood Cancer
16.6.2.3.2.8.Lung Cancer
16.6.2.3.2.9.Others
16.6.2.3.3.Pharamacogenomics
16.6.2.3.4.Hematopathology
16.6.2.3.5.Genetic Testing
16.6.2.3.6.Neurological Diseases
16.6.2.3.7.Cardiovascular Diseases
16.6.2.3.8.Others
16.6.2.4.Argentina Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.2.4.1.Clinical Laboratories
16.6.2.4.2.Pharmaceutical and Biotechnology Companies
16.6.2.4.3.Research Institutions
16.6.3.Rest of Latin America
16.6.3.1.Rest of Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Offerings
16.6.3.1.1.Instruments
16.6.3.1.2.Solutions
16.6.3.1.3.Reagents and Kits
16.6.3.2.Rest of Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Technology
16.6.3.2.1.Polymerase chain reaction (PCR)
16.6.3.2.2.Nucleic Acid Amplification Tests (NAATs)
16.6.3.2.3.Next-generation sequencing (NGS)
16.6.3.2.4.Fluorescence In situ hybridization
16.6.3.2.5.Microarray Technology
16.6.3.2.6.CRISP-R
16.6.3.2.7.Others
16.6.3.3.Rest of Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By Application
16.6.3.3.1.Infectious diseases
16.6.3.3.1.1.Meningitis
16.6.3.3.1.2.Chlamydia
16.6.3.3.1.3.Gonorrhea
16.6.3.3.1.4.HIV
16.6.3.3.1.5.Carbapenem-resistant Bacteria
16.6.3.3.1.6.Flu
16.6.3.3.1.7.Respiratory Syncytial Virus (RSV)
16.6.3.3.1.8.Candida
16.6.3.3.1.9.Others
16.6.3.3.2.Oncology
16.6.3.3.2.1.Breast Cancer
16.6.3.3.2.2.Prostate Cancer
16.6.3.3.2.3.Colorectal Cancer
16.6.3.3.2.4.Cervical Cancer
16.6.3.3.2.5.Kidney Cancer
16.6.3.3.2.6.Liver Cancer
16.6.3.3.2.7.Blood Cancer
16.6.3.3.2.8.Lung Cancer
16.6.3.3.2.9.Others
16.6.3.3.3.Pharamacogenomics
16.6.3.3.4.Hematopathology
16.6.3.3.5.Genetic Testing
16.6.3.3.6.Neurological Diseases
16.6.3.3.7.Cardiovascular Diseases
16.6.3.3.8.Others
16.6.3.4.Rest of Latin America Molecular Diagnostics Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.3.4.1.Clinical Laboratories
16.6.3.4.2.Pharmaceutical and Biotechnology Companies
16.6.3.4.3.Research Institutions
16.7.Key Segment for Channeling Investments
16.7.1.By Country
16.7.2.By Offerings
16.7.3.By Technology
16.7.4.By Application
16.7.5.By End Users
17.Competitive Benchmarking
17.1.Market Share Analysis, 2022
17.2.Global Presence and Growth Strategies
17.2.1.Mergers and Acquisitions
17.2.2.Product Launches
17.2.3.Investments Trends
17.2.4.R&D Initiatives
18.Player Profiles
18.1.Abbott
18.1.1.Company Details
18.1.2.Company Overview
18.1.3.Product Offerings
18.1.4.Key Developments
18.1.5.Financial Analysis
18.1.6.SWOT Analysis
18.1.7.Business Strategies
18.2.BD
18.2.1.Company Details
18.2.2.Company Overview
18.2.3.Product Offerings
18.2.4.Key Developments
18.2.5.Financial Analysis
18.2.6.SWOT Analysis
18.2.7.Business Strategies
18.3.bioMérieux SA
18.3.1.Company Details
18.3.2.Company Overview
18.3.3.Product Offerings
18.3.4.Key Developments
18.3.5.Financial Analysis
18.3.6.SWOT Analysis
18.3.7.Business Strategies
18.4.Danaher Corporation
18.4.1.Company Details
18.4.2.Company Overview
18.4.3.Product Offerings
18.4.4.Key Developments
18.4.5.Financial Analysis
18.4.6.SWOT Analysis
18.4.7.Business Strategies
18.5.DiaSorin S.p.A
18.5.1.Company Details
18.5.2.Company Overview
18.5.3.Product Offerings
18.5.4.Key Developments
18.5.5.Financial Analysis
18.5.6.SWOT Analysis
18.5.7.Business Strategies
18.6.F. Hoffmann-La Roche Ltd